Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 241 AL 255

The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies

Chiotis K, Wang Y, La Joie R, Rabinovici GD.

J Nucl Med. 2026 Feb 2;67(2):175-185. doi: 10.2967/jnumed.124.268339.

Balancing Speed and Sensitivity: Echo-Planar Accelerated MRI for ARIA-H Screening in Anti-Aβ Therapeutics

Hagiwara A.

Invest Radiol. 2026 May 1;61(5):307-308. doi: 10.1097/RLI.0000000000001232.

Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model

Bhagunde P, Penner N, Willis BA, Bell R, Charil A, Irizarry MC, Hersch S, Reyderman L.

CPT Pharmacometrics Syst Pharmacol. 2026 Feb;15(2):e70173. doi: 10.1002/psp4.70173.

Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions

Zorkina Y, Abramova O, Zubkov E, Gurina O, Ushakova V.

Int J Mol Sci. 2026 Apr 16;27(8):3560. doi: 10.3390/ijms27083560.

Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Perry R, Kipps C, Soto Martín ME, Bozzali M, Logroscino G, Trafford S, Dhadda S, Kanekiyo M, Goodwin A, Hodgkinson M, Hersch S, Irizarry M, Kramer L, Froelich L.

J Prev Alzheimers Dis. 2026 Apr;13(4):100507. doi: 10.1016/j.tjpad.2026.100507. Epub 2026 Feb 13.

Predictive Model of Acupuncture Adherence in Alzheimer Disease: Secondary Analysis of Randomized Controlled Trials

Chen ZH, Li R, Jiang YH, He JK, Yan SS, Zong GH, Yi ZX, Ren XY, Jia BH.

JMIR Aging. 2026 Jan 21;9:e82787. doi: 10.2196/82787.

Antibody-based nanoparticles in Alzheimer's disease: Innovations in diagnosis and therapy

Patwekar F, Patwekar M, Wei LS, Sharma R, Varghese R, Mohammed A.

Pathol Res Pract. 2026 May;281:156421. doi: 10.1016/j.prp.2026.156421. Epub 2026 Feb 24.

Alzheimer's disease and related dementias in rural medicare populations: a scoping review

Kianfar N, Alsharayri S, Mollalo A.

BMC Geriatr. 2026 Jan 27;26(1):237. doi: 10.1186/s12877-026-07031-7.

Behavioral Variant in Alzheimer's Disease

Wu CK, Dailey JM, Donahue JE.

Acta Neurol Taiwan. 2026 Jan 1;35(1):14-24. doi: 10.4103/ant.ANT-D-25-00098. Epub 2026 Jan 29.

Chronic stress, gut dysbiosis, and cholesterol metabolism: Implications for Alzheimer's disease

Das A, P N, Chowdhury D, Das A, Manna R, Bodakhe SH.

J Neuroimmunol. 2026 Apr;413:578853. doi: 10.1016/j.jneuroim.2026.578853. Epub 2026 Jan 6.

Neurobiological links between Alzheimer's disease and reward system dysfunction

Harutyunyan H, Minasyan R, Kalueff AV, Yenkoyan KB.

Neuroscience. 2026 May 25;603:57-68. doi: 10.1016/j.neuroscience.2026.03.028. Epub 2026 Mar 22.

[Alzheimer's disease: Diagnostic criteria and their evolution]

Vorobev SV, Emelin AY, Yanishevskiy SN, Tantasheva AM.

Zh Nevrol Psikhiatr Im S S Korsakova. 2026;126(4. Vyp. 2):29-39. doi: 10.17116/jnevro202612604229.

Cognition, Diagnosis, and Treatment of Alzheimer's Disease: A Review

Qin Y, Deng X, Zhang S.

Recent Pat Biotechnol. 2026;20(2):260-280. doi: 10.2174/0118722083358924250606173812.

Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications

Vossel K, Johnson EL, Cretin B, Matsumoto R.

Lancet Neurol. 2026 Mar;25(3):294-307. doi: 10.1016/S1474-4422(25)00425-9. Epub 2026 Jan 22.

Cognitive and Brain Reserve as Modifiers of Early Alzheimer Disease-Related Cognitive Vulnerability

Sewell KR, Solis-Urra P, Huang H, Karikari TK, Grove G, Kramer AF, McAuley E, Burns JM, Hillman CH, Vidoni ED, Morris JK, Marsland AL, Kang C, Sutton BP, Wan L, Kamboh MI, Gianaros PJ, Drake JA, Stern Y, Oberlin LE, Erickson KI.

Neurology. 2026 May 12;106(9):e214833. doi: 10.1212/WNL.0000000000214833. Epub 2026 Apr 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias